1
|
Launay O, Ndiaye AGW, Conti V, Loulergue P, Sciré AS, Landre AM, Ferruzzi P, Nedjaai N, Schütte LD, Auerbach J, Marchetti E, Saul A, Martin LB, Podda A. Booster Vaccination With GVGH Shigella sonnei 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial. Front Immunol 2019; 10:335. [PMID: 30906291 PMCID: PMC6418009 DOI: 10.3389/fimmu.2019.00335] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 02/08/2019] [Indexed: 11/18/2022] Open
Abstract
The investigational Shigella sonnei vaccine (1790GAHB) based on GMMA (generalized modules for membrane antigens) is immunogenic, with an acceptable safety profile in adults. However, pre-vaccination anti-S. sonnei lipopolysaccharide (LPS) antibody levels seemed to impact vaccine-related immune responses. This phase 1, open-label, non-randomized extension study (ClinicalTrials.gov: NCT03089879) evaluated immunogenicity of a 1790GAHB booster dose in seven adults with undetectable antibodies prior to priming with three 1790GAHB vaccinations 2–3 years earlier (boosted group), compared to one dose in 28 vaccine-naïve individuals (vaccine-naïve group). Anti-S. sonnei LPS serum IgG geometric mean concentrations and seroresponse (increase of ≥25 EU or ≥50% from baseline antibody ≤ 50 EU and ≥50 EU, respectively) rates were calculated at vaccination (day [D]1), D8, D15, D29, D85. Safety was assessed. Geometric mean concentrations at D8 were 168 EU (boosted group) and 32 EU (vaccine-naïve group). Response peaked at D15 (883 EU) and D29 (100 EU) for the boosted and vaccine-naïve groups. Seroresponse rates at D8 were 86% (boosted group) and 24% (vaccine-naïve group) and increased at subsequent time points. Across both groups, pain (local) and fatigue (systemic) were the most frequent solicited adverse events (AEs). Unsolicited AEs were reported by 57% of boosted and 25% of vaccine-naïve participants. No deaths, serious AEs, or AEs of special interest (except one mild neutropenia case, possibly vaccination-related) were reported. One 1790GAHB dose induced a significant booster response in previously-primed adults, regardless of priming dose, and strong immune response in vaccine-naïve individuals. Vaccination was well tolerated.
Collapse
Affiliation(s)
- Odile Launay
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Inserm CIC 1417, F-CRIN I-REIVAC, Paris, France.,Assistance Publique Hôpitaux de Paris, CIC Cochin-Pasteur, Paris, France
| | | | | | - Pierre Loulergue
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Inserm CIC 1417, F-CRIN I-REIVAC, Paris, France.,Assistance Publique Hôpitaux de Paris, CIC Cochin-Pasteur, Paris, France
| | | | - Anais Maugard Landre
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Inserm CIC 1417, F-CRIN I-REIVAC, Paris, France.,Assistance Publique Hôpitaux de Paris, CIC Cochin-Pasteur, Paris, France
| | | | - Naouel Nedjaai
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Inserm CIC 1417, F-CRIN I-REIVAC, Paris, France.,Assistance Publique Hôpitaux de Paris, CIC Cochin-Pasteur, Paris, France
| | | | | | | | - Allan Saul
- GSK Vaccines Institute for Global Health, Siena, Italy
| | | | - Audino Podda
- GSK Vaccines Institute for Global Health, Siena, Italy
| |
Collapse
|
2
|
Obiero CW, Ndiaye AGW, Sciré AS, Kaunyangi BM, Marchetti E, Gone AM, Schütte LD, Riccucci D, Auerbach J, Saul A, Martin LB, Bejon P, Njuguna P, Podda A. A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country. Front Immunol 2017; 8:1884. [PMID: 29375556 PMCID: PMC5763125 DOI: 10.3389/fimmu.2017.01884] [Citation(s) in RCA: 81] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Accepted: 12/11/2017] [Indexed: 01/08/2023] Open
Abstract
Shigellosis is a mild-to-severe diarrheal infection, caused by the genus Shigella, and is responsible for significant morbidity and mortality worldwide. We evaluated the safety and immunogenicity of an investigational Shigella sonnei vaccine (1790GAHB) based on generalized modules for membrane antigens (GMMA) in Kenya, a Shigella-endemic country. This phase 2a, observer-blind, controlled randomized study (NCT02676895) enrolled 74 healthy adults aged 18–45 years, of whom 72 were vaccinated. Participants received, in a 1:1:1 ratio, two vaccinations with the 1790GAHB vaccine at doses of either 1.5/25 μg of O antigen (OAg)/protein (group 1.5/25 μg) or 5.9/100 μg (group 5.9/100 μg) at day (D) 1 and D29, or vaccination with a quadrivalent meningococcal vaccine at D1 and tetanus, diphtheria, and acellular pertussis vaccine at D29 (control group). Solicited and unsolicited adverse events (AEs), serious AEs (SAEs), and AEs of special interest (neutropenia and reactive arthritis) were collected. Anti-S. sonnei lipopolysaccharide (LPS) serum immunoglobulin G (IgG) geometric mean concentrations (GMC) were evaluated at D1, D29, and D57 and compared to anti-S. sonnei LPS antibody levels in convalescent patients naturally exposed to S. sonnei. The percentages of participants with seroresponse were also calculated. The most frequently reported solicited local and systemic AEs across all groups were pain and headache, respectively. Only one case of severe systemic reaction was reported (severe headache after first vaccination in group 5.9/100 μg). Seven and three episodes of neutropenia, assessed as probably or possibly related to vaccination respectively, were reported in the investigational and control groups, respectively. No other SAEs were reported. Despite very high baseline anti-S. sonnei LPS serum IgG levels, the 1790GAHB vaccine induced robust antibody responses. At D29, GMC increased 2.10- and 4.43-fold from baseline in groups 1.5/25 and 5.9/100 μg, respectively, whereas no increase was observed in the control group. Antibody titers at D57 were not statistically different from those at D29. Seroresponse was 68% at D29 and 90% at D57 in group 1.5/25 μg, and 96% after each vaccination in group 5.9/100 μg. The 1790GAHB vaccine was well tolerated and highly immunogenic in a population of African adults, regardless of the GMMA OAg/protein content used.
Collapse
Affiliation(s)
- Christina W Obiero
- KEMRI-Wellcome Trust Research Programme, Clinical Research Department, Kilifi, Kenya
| | | | | | - Bonface M Kaunyangi
- KEMRI-Wellcome Trust Research Programme, Clinical Research Department, Kilifi, Kenya
| | | | - Ann M Gone
- KEMRI-Wellcome Trust Research Programme, Clinical Research Department, Kilifi, Kenya
| | | | | | | | - Allan Saul
- GSK Vaccines Institute for Global Health, Siena, Italy
| | | | - Philip Bejon
- Clinical Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Headington, United Kingdom
| | - Patricia Njuguna
- KEMRI-Wellcome Trust Research Programme, Clinical Research Department, Kilifi, Kenya.,Department of Public Health, Pwani University, Kilifi, Kenya
| | - Audino Podda
- GSK Vaccines Institute for Global Health, Siena, Italy
| |
Collapse
|
3
|
Schütte LD, Baumeister S, Weis B, Hudemann C, Hanschmann EM, Lillig CH. Identification of potential protein dithiol-disulfide substrates of mammalian Grx2. Biochim Biophys Acta Gen Subj 2013; 1830:4999-5005. [DOI: 10.1016/j.bbagen.2013.07.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Revised: 07/02/2013] [Accepted: 07/08/2013] [Indexed: 12/24/2022]
|
4
|
Hanschmann EM, Lönn ME, Schütte LD, Funke M, Godoy JR, Eitner S, Hudemann C, Lillig CH. Both thioredoxin 2 and glutaredoxin 2 contribute to the reduction of the mitochondrial 2-Cys peroxiredoxin Prx3. J Biol Chem 2010; 285:40699-705. [PMID: 20929858 PMCID: PMC3003369 DOI: 10.1074/jbc.m110.185827] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2010] [Revised: 10/05/2010] [Indexed: 12/31/2022] Open
Abstract
The proteins from the thioredoxin family are crucial actors in redox signaling and the cellular response to oxidative stress. The major intracellular source for oxygen radicals are the components of the respiratory chain in mitochondria. Here, we show that the mitochondrial 2-Cys peroxiredoxin (Prx3) is not only substrate for thioredoxin 2 (Trx2), but can also be reduced by glutaredoxin 2 (Grx2) via the dithiol reaction mechanism. Grx2 reduces Prx3 exhibiting catalytic constants (K(m), 23.8 μmol·liter(-1); V(max), 1.2 μmol·(mg·min)(-1)) similar to Trx2 (K(m), 11.2 μmol·liter(-1); V(max), 1.1 μmol·(mg·min)(-1)). The reduction of the catalytic disulfide of the atypical 2-Cys Prx5 is limited to the Trx system. Silencing the expression of either Trx2 or Grx2 in HeLa cells using specific siRNAs did not change the monomer:dimer ratio of Prx3 detected by a specific 2-Cys Prx redox blot. Only combined silencing of the expression of both proteins led to an accumulation of oxidized protein. We further demonstrate that the distribution of Prx3 in different mouse tissues is either linked to the distribution of Trx2 or Grx2. These results introduce Grx2 as a novel electron donor for Prx3, providing further insights into pivotal cellular redox signaling mechanisms.
Collapse
Affiliation(s)
- Eva-Maria Hanschmann
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| | - Maria Elisabet Lönn
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| | - Lena Dorothee Schütte
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| | - Maria Funke
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| | - José R. Godoy
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| | - Susanne Eitner
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| | - Christoph Hudemann
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| | - Christopher Horst Lillig
- From the Institut für Klinische Zytobiologie und Zytopathologie, Fachbereich Medizin, Philipps Universität, DE-35037 Marburg, Germany
| |
Collapse
|